We've got a lot of vaccine news this morning.
Let's start with AstraZeneca.
AstraZeneca and Oxford University published promising data from an early-stage trial of a key coronavirus vaccine study Monday in London.
The details, published in the U.K. medical journal The Lancet, showed what the two groups described as humoral and cellular immune responses in human trial, with an acceptable safety profile. The study also showed 'potent' cellular and humoral immunogenicity in all 1,077 participants in the Phase 1/Phase II study.
'The interim Phase I/II data for our coronavirus vaccine shows that the vaccine did not lead to any unexpected reactions and had a similar safety profile to previous vaccines of this type," said Andrew Pollard, chief investigator of the Oxford Vaccine Trial at Oxford University and co-author of the trial. "The immune responses observed following vaccination are in line with what we expect will be associated with protection against the SARS-CoV-2 virus, although we must continue with our rigorous clinical trial programme to confirm this."
And then there's Pfizer.
Pfizer, which is working on two candidates from its mRNA-based vaccine program in collaboration with Germany's BioNTech, will supply 30 million doses to the U.K.--at an undisclosed price--once approved by regulators.
But on Monday, U.K. Prime Minister Boris Johnson said that it would be an “exaggeration" to suggest that a vaccine would be available by "this year or next ... We're not there yet".
Pfizer CEO Albert Bourla said, “This agreement is a testament to our shared goal to have millions of doses of a vaccine against COVID-19 available before the end of the year...We would like to thank the U.K. government for its commitment and support in helping to protect the people of the United Kingdom from this deadly virus.”
Last week, Pfizer received 'fast track' designation by the U.S. Food and Drug Administration for its vaccine candidates based on preliminary data from Phase 1 and Phase 2 studies earlier this month. Early data from the German trials are expected to be released in July, Pfizer said at the time.
Earlier this month, Pfizer said preliminary results of its coronavirus vaccine study that it said triggered a 'strong immune response' in human trials, and unveiled plans to test the most promising of its four vaccine candidates on up to 30,000 participants in trials set for the United States and Europe.
Jim Cramer this morning said that investors should perhaps consider "calls instead of common."
What's his advice here?
Watch the video above for more.
Latest Videos From TheStreet and Jim Cramer: